3SOF

I bought @ .24 Looks like the bottom is .19. The risk reward appears good.

I like the volume today! I'm looking to break and close above .265 resistance with in a day or two. Then I'm looking for a .30+ close. Next .37+.
Plan to sell @ or near .43 or a close below .19

I'm in MOVI since 1.92 for the last three weeks. I've got to love it! But, this is very volatile. It is going to take a nose dive. Don't know when. I'm posting the weekly chart. Notice the nose dive on Aug. 11th.

Could now be the time to re-enter INSM?

NIHK is looking good, breaking out on 2 days of increasing volume. A close above .062 would be very bullish. I've been holding this one for months.

WOW! what a move today. And, without any news. I've been holding glif for months. Anyone else been holding or bought in today? I'm looking for a probable sell off tomorow, but I'm still going to hold.

GLIF is making a huge move today with over 20MIL in volume!

Quote from: OneStockMind on April 13, 2006, 04:40:39 PM

I'm so glad to finally see some movement on NIHK since it started to stink in my portfolio.
In at .141.

I forgot Friday was Good Friday!

It started to stink in my portfolio also, In @ .125. And, .09 in my Roth IRA.

Happy Easter everyone

NIHK closed @ .104 up 22%, the high of the day with higher than average volume and broke the downward trend. Hopefully, tomorrow will be a runner.

GLIF moving. Up 20% on the news!


Press Release Source: Grant Life Sciences


Grant Life Sciences ('Grant') enters into a Memorandum of Understanding with Diagnostic Technologies Ltd. ('DTL') to develop and commercialize Grant's cervical cancer-diagnostic technology
Wednesday April 12, 9:35 am ET


LOS ANGELES--(BUSINESS WIRE)--April 12, 2006--Grant Life Sciences Inc.
The proposed deal would include upfront payment of $250,000 to Grant, plus ongoing royalties upon commercialization of the resulting product; also, DTL will conduct and fund all development costs, including clinical trials, associated with the commercialization of the products developed from Grant's cervical cancer diagnostic technology

ADVERTISEMENT


Grant Life Sciences Inc. (OTC Bulletin Board: GLIF - News) announced today that it has entered into a Memo of Understanding (MOU) with Israel-based Diagnostic Technologies Ltd. (DTL) related to Grant's cervical cancer-diagnostic technology (U.S. Patent No. 6,743,593). Under the MOU, Grant will receive an upfront licensing fee of $250,000. In addition, the MOU calls for DTL to conduct all development at its own cost, including clinical trials, associated with the commercialization of the products developed from Grant's cervical cancer-diagnostic technology. Upon commercialization, DTL will pay Grant an ongoing royalty on sales of the products developed, according to the MOU.

A definitive licensing agreement will be signed following appropriate due diligence and a feasibility test. Upon signing, DTL will immediately assume all of the costs associated with turning Grant's core technology related to cervical-cancer diagnostics into a commercially viable product. The diagnostic product based on Grant's technology will augment and complement DTL's suite of diagnostics aimed at the women's health market. Stan Yakatan, Grant's Chairman, together with DTL's Chairman, were instrumental in structuring this MOU, recognizing the considerable synergy of the relationship between the companies.

"This event, once consummated, will represent a most important milestone in the evolution of our company," said Hun-Chi Lin, Ph.D., Grant's President and Chief Scientist. "To date, we have been hampered in our development of our cervical cancer-technology because of capital constraints. The large costs of development, as well as the considerable expenses associated with being a publicly traded company, have hampered our ability to expedite final development of our core technology. This affiliation with DTL will help us accomplish many of our goals and more readily assure success and hoped-for shareholder value appreciation."

"We are happy with the opportunity to extend our current knowledge in developing diagnostic tools and means in the field of women's health to the field of cervical cancer and to fast-forward development and commercialization of a diagnostic product based on Grant's cervical cancer diagnosis technology," said Hamutal Meiri, Ph.D., Chief Executive Officer of DTL. "We hope that their technology will enable the detection of the presence of antibodies produced only by cancer-causing HPV-types and profile them." According to the National Cancer Institute there are some 100 types of HPV. However, only about 7 to 15 of these appear to cause cervical cancer, with certain HPV-types especially virulent in this regard. Cancer-causing HPV-types express certain unique proteins that help trigger the disease. The parties to the MOU believe that the product developed using Grant's technology can distinguish these cancer-causing proteins from those made by non-cancer-causing HPV-types. DTL therefore expects that using Grant's technology will enable it to determine whether a woman has cervical cancer or pre-cervical cancer conditions.

"Upon consummation of this partnership with DTL, Grant will have the 'luxury' of being able to focus its efforts on boosting revenues from sales in Asia of its rapid AccuDx tests for Malaria and Dengue Fever," added Stan Yakatan, Chairman of Grant. "These products, along with its rapid AccuDx tests for HIV-1 and HIV-2, represent an impressive product portfolio, and Grant will be able to look to drive new-business development for Grant Life Sciences in Asia. In addition, the market for cervical cancer testing is enormous, and DTL intends to carry a focused and controlled development of this innovative non-invasive, protein-based diagnostic test."

According to the American Cancer Society, the human papillomavirus (HPV) causes virtually all cervical cancer. Through its proprietary protein-based technology, the assay under development is intended to look at HPV in a fashion that identifies cervical cancer, its precursors or the likelihood of its presence. This immunotest includes antibodies especially associated with HPV-caused neoplasias or cancers that are detected with synthetic, proprietary peptides or amino acid sequences derived from certain proteins in the human papillomavirus.

About Diagnostic Technologies Ltd. (DTL)

DTL, based in Yokneam Illit, Israel, is a private company that has licensed from Technion a technology for using a highly sensitive immunoassay for the prediction of the risk to preeclampsia based on the quantitative determination of placental protein 13 (PP13) in maternal serum for prediction pregnancy disorders. The current test is aimed for the prediction of the risk for preeclampsia. According to the CDC, preeclampsia affects five to seven percent of all pregnant women and represents a serious challenge for obstetricians and prenatal and diagnostic laboratories. This threatening disorder can result in: loss of life; blindness; motor and mental disorders or premature newborns; pregnancy hypertension; and kidney, liver & cardiovascular malfunctioning. It is estimated that nearly $30 billion is spent today in healthcare costs to treat women with preeclampsia and their newborns. The company's in vitro ELISA-based test utilizes a simple blood test for the early prediction of preeclampsia, and it is now in clinical trials. TEUZA, an Israeli venture fund, is the major investor in the Company. On Jan. 31, 2006, PerkinElmer, Inc. (NYSE: PKI - News), a world leader in Health Sciences and Photonics, announced that it has secured the exclusive global rights to PP13 for identifying patients at risk for preeclampsia developed by DTL.

About Grant Life Sciences Inc.

Grant Life Sciences Inc. develops products to improve the efficiency of detecting and diagnosing cervical cancer, including a sensitive, reliable, non-invasive, point-of-care test. The diagnostic assay being developed by the Company has shown promise in detecting cervical cancer and its precursors, a disease that kills in excess of 300,000 women annually. According to the CDC there are currently more than 120 million cervical screening tests administered annually in the U.S. and Europe. In developed nations more than 120 million eligible women, 20 years old and above, still do not get Pap smears, and globally more than 1.7 billion over the age of 20 have never been checked due to cultural, religious or economic reasons. Further information is available at: www.grantlifesciences.com.

I believe I made a big mistake, I should have took profits during it's recent run up. The price is currently @ the level I made my first purchase, .0104. Furthermore, I did what "good traders" do and averaged(doubled) up @ .0155. now I'm in the hole. Oh well, you win some and lose some. Will hold until the next run up!!

Thanks for everyone's posts.

Good luck to all!

Quote from: LiveLife on April 02, 2006, 12:28:37 PM
john b mcginnis,

Yes, penny stocks are often volatile and should only be "speculated."  However, unlike many penny stocks that don't have any marketed products/services, GameZnFlix already has marketed products/services.  The reason why Circuit City went nationwide with this tiny startup company (like they did with Netflix several years back) is because Circuit City was confident that GameZnFlix can handle the increased DVD/game rental/sales volume the national rollout would bring.

Just think of all the questions Circuit City executives asked before going nationwide with GameZnFlix.  So ask yourself the same question, "Why did Circuit City go nationwide with GameZnFlix?"  I believe the answers are obvious.

Livelife, I agree with you, the answers are obvious. GameZnFlix is going places. But, my point was not to place all your investment dollars in one place especially penny's I don't care how good the company appears as a spectulation/investment. I have about 5% in GZFX and I might even add some, but I do remain on the conservative side. That's how I keep my investment dollars. I do read and take in your posts on  GameZnFlix.
Thanks

Quote from: jsintexas on April 01, 2006, 10:47:52 PM
I have been following this for a while. To be honest, stocks with a price this low scare me....I mean, they are at that price for a reason.  But, with that said, It looks like things are going to happen pretty soon.  Is it hard to get shares?  What should I put my limit order in at?  I am thinking of $10K or am I being a little to risky?

In my mind the dollar amount shouldn't be the question! I invest/trade minimum of 3% to a maximum of 15% of my total trading dollars + value of stocks at that time. Example: Say you have $40,000.00 invested in equities. $60,000.00 in cash. The value of your account is $100,000.00. Invest between $3,000.00 and $15,000 in each investment, 3% to %15. I've learned from experience and from 3stocksonfire not to place all your investments in one place. Where penny stocks are being played, I would stick closer to the 3%.
If all you have is $10,000.00 in investment dollars., I would still stick to a similar plan. You could lose 50 to 75% in penny's quickly. Personally, I wouldn't invest over $1500.00 in a penny with $10,000 in cash and stocks

Good luck

fill_the_gap , I have been following your posts since I've been a member of 3stocks starting May of "05" and especially following GZFX  and trust your judgement/gut feeling/evaluation of the stock. Members like you make it enjoyable to be a member, trade and make money.

Thanks, and let's go GZFX

I'm taking a chance, but I loaded up the boat with shares of NIHK on monday in my ROTH IRA @ .085. as well as still holding shares @ .12. I like what they sell. I work for a Large Fire dept. in Missouri on a Hook and Ladder company and benifit from and know the importance of the systems.They sell "low cost" alerting systems for firehouses. With the financial cut backs large and small cities are being forced to make, as well as my city, they will flock to companies like Nighthawk when they need updated alerting systems.
              http://www.nighthawksystems.com/industry/4/fire-departments

Quote

Lol i got a real kick out of the rally monkey john. 

Quote

You can't listen to the monkey very long, it becomes annoying! I found it on one of them "pump and dump" Yahoo message boards